BLA submission acceptance is expected in early 2027. An open-label study safety update is anticipated in the first quarter of 2027, followed by a potential U.S. approval in mid-2027, subject to FDA review.
If approved, Larimar is targeting a U.S. commercial launch in the third quarter of 2027. The company also expects to obtain and monetize a Rare Pediatric Disease Priority Review Voucher in mid-2027, if nomlabofusp receives approval.
